JP6276252B2 - アルツハイマー病の診断のための細胞マーカーおよびアルツハイマー病の進行の細胞マーカー - Google Patents
アルツハイマー病の診断のための細胞マーカーおよびアルツハイマー病の進行の細胞マーカー Download PDFInfo
- Publication number
- JP6276252B2 JP6276252B2 JP2015502555A JP2015502555A JP6276252B2 JP 6276252 B2 JP6276252 B2 JP 6276252B2 JP 2015502555 A JP2015502555 A JP 2015502555A JP 2015502555 A JP2015502555 A JP 2015502555A JP 6276252 B2 JP6276252 B2 JP 6276252B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cd11b
- lin
- level
- hla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261615465P | 2012-03-26 | 2012-03-26 | |
| US61/615,465 | 2012-03-26 | ||
| PCT/IL2013/050277 WO2013144957A1 (en) | 2012-03-26 | 2013-03-21 | Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015511721A JP2015511721A (ja) | 2015-04-20 |
| JP2015511721A5 JP2015511721A5 (https=) | 2016-05-12 |
| JP6276252B2 true JP6276252B2 (ja) | 2018-02-07 |
Family
ID=49258360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015502555A Active JP6276252B2 (ja) | 2012-03-26 | 2013-03-21 | アルツハイマー病の診断のための細胞マーカーおよびアルツハイマー病の進行の細胞マーカー |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20150057176A1 (https=) |
| EP (1) | EP2831584B1 (https=) |
| JP (1) | JP6276252B2 (https=) |
| KR (1) | KR20140145173A (https=) |
| CN (1) | CN104471394B (https=) |
| AU (1) | AU2013239070A1 (https=) |
| CA (1) | CA2907909A1 (https=) |
| ES (1) | ES2819174T3 (https=) |
| IL (1) | IL234779A (https=) |
| WO (1) | WO2013144957A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6312302B2 (ja) * | 2014-01-06 | 2018-04-18 | 公益財団法人ヒューマンサイエンス振興財団 | 脳梗塞の診断マーカー |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| JP6499342B2 (ja) * | 2018-03-19 | 2019-04-10 | 隆樹 日和佐 | 脳梗塞の診断マーカー |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| US20220170908A1 (en) * | 2019-03-26 | 2022-06-02 | Anton Wyss-Coray | Compositions and methods for characterizing and treating alzheimers disease |
| CN111727260A (zh) * | 2019-10-15 | 2020-09-29 | 湖南乾康科技有限公司 | 中间型单核细胞在制备诊断和预测ad药物中的应用 |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| CN112562867A (zh) * | 2021-02-22 | 2021-03-26 | 天津迈德新医药科技有限公司 | 一种预测极早期hiv感染风险的装置、存储介质和电子装置 |
| KR20240042044A (ko) | 2021-08-09 | 2024-04-01 | 뉴로퀘스트 엘티디 | 전임상 알츠하이머병을 검출하기 위한 조성물, 키트 및 방법 |
| EP4426295A1 (en) * | 2021-11-02 | 2024-09-11 | Tranquis Therapeutics, Inc. | Selection and treatment of subjects having a circulating myeloid cell inflammatory phenotype |
| KR102745500B1 (ko) * | 2022-09-02 | 2024-12-23 | 한양대학교 에리카산학협력단 | 혈액 대사체를 이용한 치매 스크리닝 장치 및 방법 |
| CN116270741B (zh) * | 2023-02-28 | 2025-10-24 | 东莞市东南部中心医院 | 骨髓源性抑制细胞在制备治疗阿兹海默症药物或试剂中的应用 |
| CN117122612B (zh) * | 2023-07-07 | 2024-08-27 | 河络新图生物科技(上海)有限公司 | 外周血单个核细胞在制备治疗/预防阿尔茨海默病的药物中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1248643E (pt) * | 2000-01-20 | 2005-10-31 | Yeda Res & Dev | Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora |
| US20020137108A1 (en) * | 2000-11-08 | 2002-09-26 | Michael Mullan | CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker in alzheimer's disease |
| IL160105A0 (en) * | 2001-12-06 | 2004-06-20 | Yeda Res & Dev | Vaccine for treatment of motor neurone diseases |
| CN100591761C (zh) * | 2004-08-19 | 2010-02-24 | 加的夫大学学院咨询有限公司 | 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途 |
| CN102186504B (zh) * | 2008-09-18 | 2018-04-06 | 西塞医疗中心 | 用于检测阿尔兹海默病的光学方法 |
| US20130230499A1 (en) * | 2010-03-10 | 2013-09-05 | Michal Eisenbach-Schwartz | Cellular blood markers for early diagnosis of als and for als progression |
-
2013
- 2013-03-21 WO PCT/IL2013/050277 patent/WO2013144957A1/en not_active Ceased
- 2013-03-21 CA CA2907909A patent/CA2907909A1/en not_active Abandoned
- 2013-03-21 ES ES13767635T patent/ES2819174T3/es active Active
- 2013-03-21 US US14/388,369 patent/US20150057176A1/en not_active Abandoned
- 2013-03-21 JP JP2015502555A patent/JP6276252B2/ja active Active
- 2013-03-21 EP EP13767635.9A patent/EP2831584B1/en active Active
- 2013-03-21 AU AU2013239070A patent/AU2013239070A1/en not_active Abandoned
- 2013-03-21 KR KR1020147029916A patent/KR20140145173A/ko not_active Withdrawn
- 2013-03-21 CN CN201380027520.5A patent/CN104471394B/zh active Active
-
2014
- 2014-09-22 IL IL234779A patent/IL234779A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US20150057176A1 (en) | 2015-02-26 |
| ES2819174T3 (es) | 2021-04-15 |
| EP2831584B1 (en) | 2020-06-17 |
| EP2831584A1 (en) | 2015-02-04 |
| CA2907909A1 (en) | 2013-10-03 |
| JP2015511721A (ja) | 2015-04-20 |
| IL234779A (en) | 2017-12-31 |
| WO2013144957A1 (en) | 2013-10-03 |
| CN104471394A (zh) | 2015-03-25 |
| KR20140145173A (ko) | 2014-12-22 |
| CN104471394B (zh) | 2017-04-05 |
| AU2013239070A1 (en) | 2014-11-13 |
| EP2831584A4 (en) | 2015-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6276252B2 (ja) | アルツハイマー病の診断のための細胞マーカーおよびアルツハイマー病の進行の細胞マーカー | |
| JP2017535763A (ja) | マーカー群および該マーカー群の脳損傷における使用 | |
| Chen et al. | Type 1 diabetes patients have significantly lower frequency of plasmacytoid dendritic cells in the peripheral blood | |
| Martins et al. | Disease-specific expression of the serotonin-receptor 5-HT2C in natural killer cells in Alzheimer's dementia | |
| US20150209404A1 (en) | Cellular blood markers for early diagnosis of als and for als progression | |
| Miedema et al. | Circulating T cells in sarcoidosis have an aberrantly activated phenotype that correlates with disease outcome | |
| EP3467497B1 (en) | Method for analyzing expression of smn protein nuclear body | |
| WO2020232512A1 (en) | Microglial cells and methods of use thereof | |
| Nassisi et al. | Peripapillary sparing with near infrared autofluorescence correlates with electroretinographic findings in patients with Stargardt disease | |
| EP3128327B1 (en) | Method for detecting smn protein expression | |
| Frisullo et al. | The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis | |
| CN116970675A (zh) | 检测血液中衰老中性粒细胞的试剂作为精神障碍辅助诊断制剂中的应用 | |
| WO2023000688A1 (zh) | 一种阿尔茨海默病的外周血tcr标志物及其检测试剂盒和应用 | |
| Ma et al. | Terminally differentiated cytotoxic CD4+ T cells were clonally expanded in the brain lesion of radiation‐induced brain injury | |
| US20240369555A1 (en) | Method of evaluating progression of an infectious disease and/or inflammatory disease | |
| Rodríguez-Martín et al. | Diagnosis of Diffuse Interstitial Lung Diseases: BAL Study-Its Utility for the Diagnosis | |
| JP6763611B2 (ja) | アスベスト曝露歴または中皮腫の検査方法 | |
| AL-Sadi et al. | Profile of auto-antibodies (Anti-tissue transglutaminase and anti-deamidated gliadin peptide antibodies) and Interleukin-18 in the serum of celiac patients and their relationship with small intestinal mucosal injury | |
| Yu et al. | Predictive value of peripheral blood lymphocytes for glaucoma susceptibility: a clinical observational study | |
| CN117230144A (zh) | 抑郁症诊断、药物治疗效果预测的生物标志物 | |
| WO2023118575A1 (en) | Method for determining basophil activation in a sample | |
| Vitiligo | Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases | |
| EP1881326A1 (en) | Myeloid progenitor cells for diagnosis of central nervous system diseases | |
| Younkin et al. | Trisha M. Stan1, Philipp A. Jaeger1, Markus Britschgi1, Daniela Berdnik1, Ruo-Pan Huang2, Bradley F. Boeve3, Adam L. Boxer4, Nicole Finch5, Gabriela K. Fragiadakis6, Robert Bruggner6, Neill R. Graff-Radford5, Ruochun Huang4, Hudson Johns1, Anna Karydas4, David S. Knopman3, Michael Leipold6, 7, Holden Maecker6, 7, Zachary Miller4, Ronald C. Petersen5, Rosa Rademakers5, Chung-Huan Sun1, Steve | |
| JP2021528075A (ja) | 腎移植後のｂｋウイルス腎症のリスクの層別化方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160317 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160317 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170214 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170419 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170706 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171219 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180111 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6276252 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |